Speed of genetic testing for children with immune disease
Part of Blood & lymphatic, Genetic & congenital, Immune system & allergy clinical trials.
This trial looks at whether getting genetic test results faster for children with familial hemophagocytic lymphohistiocytosis (FHL) can help them get a bone marrow transplant sooner and improve survival. It compares the usual wait for genetic results to a quicker, ultra-fast testing method.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must be under 18 years old
- Have a confirmed or suspected diagnosis of FHL or related genetic condition, or a family history of it
- Must have at least 5 of 8 HLH symptoms or lab findings (like fever, enlarged spleen, low blood counts)
- Must be covered by social security in France
- Parent or guardian must sign consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new gene therapy for a rare immune disorder called familial hemophagocytic lymphohistiocytosis (HLH) type 3, caused by mutations in the UNC13D gene. Your own blood stem cells are modified in the lab to carry a working copy of the gene, then given back to you after a mild chemotherapy, aiming to fix the immune problem without needing a bone marrow transplant.
This trial uses a rapid type of genetic testing (whole genome sequencing) to look at the DNA of children and young adults with cancer. The goal is to better understand each person's cancer and potentially guide treatment decisions.
This study is for people with hemophagocytic lymphohistiocytosis (HLH), a condition where the immune system becomes overactive. Researchers want to collect medical data and blood samples to better understand HLH and find better ways to diagnose and treat it.
This trial looks for a DNA marker in people with HLH caused by lymphoma. It may help doctors better confirm the cause of HLH and guide treatment decisions.
This trial tests a combination of a targeted drug (ruxolitinib) with a less intense version of standard chemo for adults with Hemophagocytic Lymphohistiocytosis (HLH). It aims to control the overactive immune response while reducing side effects.
This trial looks at how people with lymphoma-related hemophagocytic lymphohistiocytosis (HLH) respond to treatment. It aims to better describe expected outcomes and who benefits most, which may help guide future care.
Hear when a new Familial Lymphohistiocytosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.